摘要
目的 探讨冠心病心绞痛患者体内纤溶系统的变化并分析其临床意义.方法 对110例冠心病心绞痛患者体内的纤溶酶原激活物抑制剂-1（PAI-1）、组织型纤溶酶原激活剂（t-PA）、纤维蛋白原（FIB）水平进行检测,并与20例正常对照者进行对照.结果 冠心病组PAI-1、FIB水平分别为（400±90）AU/L,（4.80±1.1）g/L,明显高于对照组[分别为（260±80）AU/L,（3.6±1.0）g/L,均P＜0.05];冠心病组t-PA水平为（240±70）IU/L,明显低于对照组[（290±90）IU/L,P＜0.01）].不稳定型心绞痛患者（70例）PAI-1、FIB水平明显高于稳定型心绞痛患者（40例,均P＜0.05）;不稳定型心绞痛患者t-PA水平明显低于稳定型心绞痛患者（P＜0.01）.心绞痛发作者（64例）PAI-1、FIB明显高于无心绞痛发作者（46例,均P＜0.05）;而t-PA水平明显低于无心绞痛发作者（P＜0.01）.结论 冠心病心绞痛患者体内存在纤溶系统功能异常,尤其是在不稳定型心绞痛患者或心绞痛发作者体内更加明显,纤溶系统功能异常可能在冠心病心绞痛发病过程中起重要的作用.
Objective To observe the changes and the clinical significance of fibrinolysis in coronary heart disease（CHD） patients with angina pactoris （AP）. Methods Levels of plasmin plasminogen activator inhibitor-1（PAI-1）, tissue-type plasminogen activator（ t-PA）, fibrinogen （FIB）in 110 CHD patients with AP and 20 normal cases as control group were analyzed. Results Levels of PAI-1, FIB in CHD patients with AP[（260 ± 8 ） AU/L,（3.6 ± 1.0） g/L] were significantly higher than those in control cases [（260 ± 8 ） AU/L, （3.6 ± 1.0 ） g/L], and those of t-PA were significantly lower than those in control cases. Level of t-PA in patients with coronary heart disease [（240 ± 7） IU/L] was significantly lower than that in the control group[（290 ± 9） IU/L,P 〈 0. 01]. Levels of PAI-1 ,FIB in unstable angina（UA） patients with UA heart events were significantly higher than those in patients with stable angina （SA）. Level of t-PA in patients with UA was significantly lower than that in patients with SA （P 〈0. 01 ）. Levels of PAI-1, FIB in patients with AP events were significantly higher than those in patients without AP events. Levels of t-PA in patients with AP were significantly lower than those in patients without AP events.Conclusions There is abnormal fibrinolysis function in CHD patients with AP, specially in patients with UA or with AP events, which might be play an important rule in coronary heart disease （CHD） patients with angina pactoris.
出处
《中国医药》
2011年第1期3-4,共2页
China Medicine
基金
海南省自然科学基金指导性计划项目（806109）
海南省卫生厅科研立项课题
